Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Rezivertinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 19/20 | 0.78 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.78 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.78 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.78 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.78 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.78 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.78 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.78 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.78 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.78 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.78 |
| ▸ | GHSR known ✓ | Q92847 | 1/20 | 0.78 |
| ▸ | MLNR | O43193 | 1/20 | 0.78 |
| ▸ | KDM1A | O60341 | 1/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.78 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.78 |
| ▸ | INSR | P06213 | 1/20 | 0.78 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.78 |
| ▸ | NQO2 | P16083 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rezivertinib SCHEMBL19586825 | 1.00 | EGFR (0.78) | EGFRMLNRKDM1AABCB11ERBB2 | |
| Rezivertinib SCHEMBL19717941 | 0.99 | EGFR (0.78) | EGFRMLNRKDM1AABCB11ERBB2 | |
| Rezivertinib SCHEMBL29462581 | 0.97 | EGFR (0.82) | EGFRMLNRKDM1AABCB11ERBB2 | |
| Rezivertinib SCHEMBL17553564 | 0.97 | EGFR (0.82) | EGFRMLNRKDM1AABCB11ERBB2 | |
| Rezivertinib SCHEMBL19717897 | 0.97 | EGFR (0.81) | EGFRMLNRKDM1AABCB11ERBB2 | |
| Rezivertinib SCHEMBL19717972 | 0.94 | EGFR (0.71) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL24637302 | 0.92 | EGFR (0.73) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL17831565 | 0.92 | EGFR (0.73) | EGFRMLNRKDM1AABCB11ERBB2 | |
| Osimertinib SCHEMBL14661152 | 0.91 | EGFR (0.95) | EGFRMLNRKDM1AABCB11ERBB2 | |
| Osimertinib SCHEMBL29375936 | 0.91 | EGFR (0.95) | EGFRMLNRKDM1AABCB11ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12390464-B2 | Treatment of EGFR mutant-related cancers using a combination of EGFR and CDK4/6 inhibitors | BETA PHARMA, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20220347177-A1 | TREATMENT OF EGFR MUTANT-RELATED CANCERS USING A COMBINATION OF EGFR AND CDK4/6 INHIBITORS | BETA PHARMA, INC. | 2022-11-03 | — | — | US | disclosed |
| EP-4034121-A1 | TREATMENT OF EGFR MUTANT-RELATED CANCERS USING A COMBINATION OF EGFR AND CDK4/6 INHIBITORS | Beta Pharma, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390464-B2 | Treatment of EGFR mutant-related cancers using a combination of EGFR and CDK4/6 inhibitors | EGFR, CDK4, ERBB4 | EGFR 1/4885HTR1A 4452/4885DRD2 4767/4885 |
| US-20220347177-A1 | TREATMENT OF EGFR MUTANT-RELATED CANCERS USING A COMBINATION OF EGFR AND CDK4/6 INHIBITORS | EGFR, CDK4, ERBB4 | EGFR 1/4885HTR1A 4452/4885DRD2 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.